Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma by Oliva, Marc et al.
REVIEW
Immune biomarkers of response to immune-
checkpoint inhibitors in head and neck squamous cell
carcinoma
M. Oliva1,2, A. Spreafico1,2, M. Taberna3,4, L. Alemany5,6, B. Coburn7,8, R. Mesia9 & L. L. Siu1,2*
1Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto; 2University of Toronto, Toronto, Canada; 3Medical Oncology
Department, Catalan Institute of Oncology (ICO), ONCOBELL-IDIBELL, L’Hospitalet de Llobregat, Barcelona; 4Barcelona University, Barcelona; 5Cancer Epidemiology
Research Program, Catalan Institute of Oncology (ICO), IDIBELL, L’Hospitalet de Llobregat, Barcelona; 6CIBER in Epidemiology and Public Health (CIBERESP),
Barcelona, Spain; 7Division of Infectious Diseases, University Health Network, Toronto; 8Departments of Medicine and Laboratory of Medicine and Pathobiology,
University of Toronto, Toronto, Canada; 9Medical Oncology Department, B-ARGO Group, Catalan Institute of Oncology (ICO), Badalona, Spain
*Correspondence to: Prof. Lillian L. Siu, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, 700 University Avenue, Suite 7-624, Toronto, ON
M5G 1Z5, Canada. Tel: þ1-416-946-2911; Fax: þ1-416-946-4467; E-mail: lillian.siu@uhn.ca
Anti-programmed cell death protein 1 (PD-1) agents have become the standard of care for platinum-refractory recurrent/
metastatic head and neck squamous cell carcinoma (HNSCC) and are currently being evaluated in various disease settings.
However, despite the gain in overall survival seen in some of the clinical trials, the majority of patients display primary resistance
and do not benefit from these agents. Taking into consideration the potentially severe immune-related toxicities and their high
cost, the search for predictive biomarkers of response is crucial. Besides Programmed death ligand-1 (PD-L1) expression, other
biomarkers such as immune infiltration, tumor mutational burden or immune-gene expression profiling have been explored,
but none of them has been validated in this disease. Among these, the microbiota has recently garnered tremendous interest
since it has proven to influence the efficacy of PD-1 blockade in some tumor types. With the accumulating evidence on the
effect of the microbiota in HNSCC tumorigenesis and progression, the study of its potential role as a predictive immune
biomarker is warranted. This review examines the available evidence on emerging immune predictive biomarkers of response
to anti-PD-1/PD-L1 therapy in HNSCC, introducing the microbiota and its potential use as a predictive immune biomarker in this
disease.
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Introduction
Immune-checkpoint inhibitors (ICI) targeting cytotoxic T-
lymphocyte antigen 4 and programmed cell death protein-1 (PD-
1) and its ligands, programmed death ligand-1 (PD-L1)/2, have
shown a significant and consistent benefit in survival when com-
pared with standard therapies in prospective randomized clinical
trials, leading to their regulatory approval in multiple tumor
types [1–5]. In head and neck squamous cell carcinoma
(HNSCC), anti-PD-1 antibodies are the first immunotherapeutic
agents to demonstrate evidence of response durability and sur-
vival benefit in platinum-pretreated recurrent and metastatic (R/
M) disease [6–9]. However, despite the encouraging results
which led to the approval of nivolumab and accelerated approval
of pembrolizumab by the US Food and Drug Administration
(FDA) for platinum-refractory R/M HNSCC, the overall re-
sponse rates (ORRs) of these agents ranged from only 13%–
18% [9, 10].
Up to 60% of patients across different tumor types, including
HNSCC, display primary resistance to anti-PD-1/PD-L1 agents
[11]. Several mechanisms have been suggested such as poor
tumor immunogenicity, limited intratumoral immune cell infil-
tration, coexpression of multiple inhibitory receptors, and induc-
tion of immunosuppressive pathways within the tumor
microenvironment (TME) [12–14]. To overcome this resistance,
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many ongoing clinical trials are evaluating combination strategies
with other immunotherapies, targeted agents, chemotherapy and
radiotherapy, not only in R/M HNSCC, but also in the locore-
gionally advanced setting (NCT02952586, NCT03040999) [15].
This is of particular relevance as a proportion of patients with R/
M HNSCC might experience rapid progression and decreased
survival when treated with single-agent anti-PD-1/PD-L1 [16].
However, the potential immune-related toxicities of ICI and
their high cost have urged the search for prospectively validated
predictive biomarkers of response including PD-L1 protein ex-
pression, intratumoral immune cell infiltration, immune-gene
expression profiling, and tumor mutational burden (TMB) [13,
14, 17]. Specifically, in HNSCC, none of them have been vali-
dated and ongoing exploration continues [9, 18].
Recently, the immunomodulatory role of the gut microbiota,
defined as the collective microorganisms inhabiting the gastro-
intestinal tract, has raised a special interest, since its composition
has proven to influence anti-PD-1 efficacy in preclinical models
and has been associated with treatment responsiveness in patients
with melanoma and some epithelial-derived tumors [19–22].
Interestingly, many retrospective studies in HNSCC have sug-
gested that the oral microbiota might also be crucial for tumor
development and progression, treatment-related toxicity and dis-
ease recurrence [23–25].
This review examines the available evidence on emerging im-
mune predictive biomarkers of response to ICI in HNSCC, intro-
ducing the microbiota and its potential use as a predictive
immune biomarker in this disease (Table 1).
Overview of emerging immune biomarkers
in HNSCC
Is PD-L1 expression a reliable biomarker of re-
sponse in HNSCC?
PD-L1þ tumors in general tend to demonstrate improved re-
sponse rates to anti-PD-1/PD-L1 therapies, in comparison to
PD-L1– tumors [26]. This correlation has been consistent with
different anti-PD-1/PD-L1 drugs across many tumor types [5, 27,
28]. Most clinical trials evaluating ICI in R/M HNSCC suggested
a similar pattern [29–31], and data from phase III randomized
trials investigating pembrolizumab in the R/M setting
Table 1. Emerging immune biomarkers of response to anti-PD-1/PD-L1 agents in HNSCC
Immune biomarkers Assay Predictive value in HNSCCa Evidence available
HPV– HPV1
PD-L1 expression PD-L1 staining by immunohisto-
chemistry in tumor cells/immune
cells (different cut-offs)
Positiveb Positiveb Prospective randomized clinical tri-
als (Table 2).
Smoking • Smokers versus nonsmokers






Retrospective analysis of prospective
trials [9].
Retrospective studies [67].
Tumor immune-cell infiltration Presence of CD8þ T cells
PD-1þ TIM-3þ CD8þ T cells




Retrospective analysis of noncon-
trolled cohorts [73].




Prospective analysis in a random-
ized clinical trial[102].








Retrospective analysis of prospective
clinical trial [74, 75].
Retrospective analysis from a non-
controlled cohort [73].
T-cell-inflamed phenotype Immune-related gene expression
signatures
Positive Positive Retrospective analysis of prospect-
ive clinical trial [74, 75, 104].
Retrospective analysis from a
noncontrolled cohort [73].
Microbiota 16S rRNA high throughput sequenc-
ing of saliva and stool
Oral microbiota: nonpredictive
Intestinal microbiota: no data yet
Retrospective analysis of prospect-
ive randomized clinical trial
[133].
aPredictive values in HPV– and HPVþ subgroups were defined positive or negative if a statistically significant correlation between response and the im-
mune biomarker was described in the referenced studies; uncertain if no significant correlation was found; no data if no studies had evaluated the role of
the biomarker in this setting at the time of this publication.
bThe positive correlation between PD-L1 expression and treatment response was not consistent across the studies.
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(KEYNOTE-040 and KEYNOTE-048) endorsed this trend by
demonstrating significantly increased survival in PD-L1þ
patients [8, 32, 33]. However, CHECKMATE-141 failed to show
a significant correlation between PD-L1 expression and tumor re-
sponse or survival when evaluating nivolumab in the platinum-
refractory R/M setting [9, 34] (Table 2).
The discordance of the results across studies might be
explained by several reasons. One of the most relevant is the lack
of uniformity in the assays and the variability in the thresholds
used to define PD-L1 positivity, which have led to the launch of
harmonization projects on PD-L1 assays by the scientific com-
munity and regulatory agencies [28, 35, 36]. This inconsistency is
evident in the development of anti-PD-1/PD-L1 agents investi-
gated to date in R/M HNSCC, including pembrolizumab, nivolu-
mab, atezolizumab, durvalumab and avelumab, thus impairing
cross-study comparisons and undermining the value of PD-L1 as
a biomarker [6, 9, 30–32, 37, 38]. Importantly, PD-L1 expression
seems to be regulated by multiple signaling pathways, including
MAPK, PI3K and Akt/PKB that are commonly altered in HNSCC
[39–41]. As a consequence of these molecular crosstalks, PD-L1
is a dynamic biomarker that is subject to temporal variations and
spatial heterogeneity. Its expression may change from the point
of initial diagnosis to recurrence or progression, and may differ
between primary and coexisting metastatic lesions [42–45].
Published reports on the intratumoral heterogeneity of PD-L1
expression in HNSCC demonstrate conflicting results [46, 47].
In HNSCC, PD-L1 is highly expressed not only by tumor cells,
but also by immune cells present in the TME, including regula-
tory T cells (Tregs), natural killer (NK) cells and antigen
presenting cells (APCs) [18, 48–51]. Across various cancer types,
it remains unclear whether PD-L1 expression and thresholds
should take into consideration all or only selected cell popula-
tions. Both pembrolizumab and atezolizumab used combined
scores based on the ratio between tumor cells and immune cells
expressing PD-L1 to define tumor PD-L1 positivity, and pembro-
lizumab did show a positive correlation with response and sur-
vival in the phase III KEYNOTE-040 study when using the
combined positive score (CPS) [52]. Recently, the results from
the phase III KEYNOTE-048 study in first line R/M HNSCC
revealed that pembrolizumab monotherapy improved OS when
compared with the EXTREME regimen in patients whose tumors
had PD-L1 expression 1% and 20% by CPS [hazard ratio
(HR) 0.78 (0.64–0.96), P¼ 0.0086 and HR 0.61 (0.45–0.83),
P¼ 0007, respectively] [33]. However, in KEYNOTE-040, the
correlation with clinical outcome was also strongly positive when
using PD-L1 expression in tumor cells only (TPS 50%), con-
gruent with the experience in non-small-cell lung cancer
(NSCLC) in KEYNOTE-010 [53, 54]. In contrast, there was no
correlation in the nivolumab CHECKMATE-141 study where
PD-L1 expression was exclusively determined in tumor cells, al-
though the thresholds used were different (>1%, 5% and 10%)
[9]. These divergent results and the limited data available suggest
no firm conclusion can be made in this regard, although CPS
seems to be more predictive than TPS in HNSCC, and the
required cut-off for the latter appears to be higher in the men-
tioned studies.
Nonetheless, it is noteworthy that, although relevant in a
smaller percentage, PD-L1– tumors also benefit from ICI [9].
Table 2. Anti-PD-1/PD-L1 agents tested in R/M HNSCC [6–9, 29–31, 33, 34, 52, 134]
Agents Target Phase/study N PD-L1
expression
Location
Cut-off ORR (%) OS (HR)a
Overall PD-L11 PD-L1- Overall PD-L11 PD-L1–
Nivolumab PD-1 III (CHECKMATE-141) 240 TCs >1% 13.3% 17% 11.8% 0.68 0.55 0.73
























































Atezolizumab PD-L1 I (GO27831) 32 ICs IC2/3: >5%
IC0/1: <5%
22% 24% 14% NA NA
aHR for OS resulting from: nivolumab and pembrolizumab versus investigator’s choice of chemotherapy (Docetaxel, Methotrexate and Cetuximab) in the
CHECKMATE-141 and KEYNOTE-040 studies, respectively; pembrolizumab monotherapy versus EXTREME regimen in the KEYNOTE-048 study; durvalumab
versus tremelimumab plus durvalumab in the CONDOR study.
ORR, overall response rate; OS, overall survival; HR, hazard ratio; TCs, tumor cells; ICs, immune cells; CPS, number of PD-L1-positive cells (tumor cells, lym-
phocytes, macrophages) divided by total number of tumor cells  100; TPS, percentage of tumor cells with membranous PD-L1 expression; NA, not ap-
plicable; Ø, no data available.
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Therefore, additional factors beyond PD-L1 expression, such as
human papillomavirus (HPV) status, tumor immune infiltration
or TMB, might also contribute to treatment response.
Are HPV1 tumors more responsive to
immunotherapy?
HPVþ oropharyngeal squamous cell carcinoma (OPSCC) is a
biologically distinct disease with better prognosis and improved
treatment responsiveness when compared with HPV– disease at
the same or similar stage [55–57]. Virus-related tumor types are
postulated to be more responsive to ICI due to intrinsic charac-
teristics including baseline tumor immunogenicity, increased
immune infiltration and increased PD-L1 expression [58, 59].
HPVþ OPSCC have been shown to have a less immunosuppres-
sive TME when compared with HPV– HNSCC, as it harbors
greater infiltration by tumor infiltrating lymphocytes (TILs),
higher proportion of CD8þ T cells, increased levels of interferon
gamma (IFN-c), decreased CD4þ/CD8þ ratio, and lower num-
bers of Tregs [60–64]. These findings can be explained by a preex-
isting adaptive host immune response against viral and tumor-
specific antigens, which may in turn lead to PD-L1 expression in
immune cells. Indeed, a recent retrospective study showed that
not only CD8þ TILs (30%) but also high PD-L1 expression in
immune cells (5%) were both favorable prognostic factors in
HPVþ disease regardless of stage [65, 66].
Altogether these findings suggest a potentially higher sensitiv-
ity of HPVþ disease to immune-checkpoint blockade. This hy-
pothesis was initially supported by the results from the HNSCC
cohort of the multibasket phase I KEYNOTE-012 trial in which
HPVþ tumors had increased ORR to pembrolizumab compared
with those that were HPV– (25%–32% versus 14%) [6, 7].
However, these results were not reproduced in the phase III
KEYNOTE-040 trial, and further studies investigating other anti-
PD-1/PD-L1 agents have reported mixed results. For instance,
increased response rates were observed among HPVþ patients
treated with durvalumab while no differences were seen with ate-
zolizumab [30, 31]. In the CHECKMATE-141 study, nivolumab
did not yield significant differences in ORR or OS between HPVþ
and HPV– patients [HR for OS 0.60 (0.37–0.97) versus 0.59
(0.38–0.92), respectively] [9, 32, 34].
The inconsistencies in the abovementioned trials might be
explained by other coexisting factors beyond PD-L1 expression
and immune infiltration. Smoking, mutational signatures and
TMB are thought to influence response to ICI in HNSCC al-
though their relevance differs between HPVþ and HPV– disease
(Table 1).
Smoking seems to contribute to a more immunosuppressive
TME and negatively impact on anti-PD-1/PD-L1 efficacy in
HNSCC. In CHECKMATE-141 study, the subgroup analysis
reported a trend toward decreased survival benefit from nivolu-
mab among smokers when compared with nonsmokers [9].
Similarly, a retrospective analysis of 81 HNSCC patients treated
with anti-PD-1/PD-L1 showed that former/current smokers were
less responsive to these agents when compared with never smok-
ers. However, this correlation only remained significant among
HPV– patients, suggesting the immunosuppressive effects of
smoking may not be as significant in HPVþ tumors [67]. In sup-
port of this, a genomic analysis of 287 HNSCC tumor samples
revealed that smoking history and tumors with high smoking
mutational signatures were correlated with decreased immune
infiltration and downregulation of immune-signaling pathways
in HPV– but not HPVþ tumors [67].
Conversely, the presence of other mutational signatures unre-
lated to smoking such as APOBEC (apolipoprotein B mRNA
editing enzyme, catalytic polypeptide-like) is of particular rele-
vance in HPVþ disease. Reduced exposure to exogenous carcino-
gens such as tobacco seems to favor the emergence of tumors
with APOBEC-driven mutations such as PI3KCA [68, 69].
Moreover, APOBEC activity is known to be crucial for innate and
adaptive immune responses, and HPV infection is thought to en-
hance it in an attempted host immune response against the virus.
In a study analyzing over 500 HNSCC tumor samples, APOBEC
mutational signatures were associated with upregulation of
immune-signaling pathways [69]. APOBEC-driven mutagenesis
might alter tumor immunogenicity in HPVþ disease impacting
on immune checkpoint efficacy. Parenthetically, the presence of
APOBEC signatures has been associated with increased immune
infiltration and PD-L1 expression in other tumor types [70–72].
Increased TMB and neoantigen load have been shown to cor-
relate with response to ICI in HPV– HNSCC, whereas most of the
studies conducted to date have refuted their predictive value in
HPVþ patients [73–75]. TMB is a quantitative measure of the
total number of coding mutations in the tumor genome.
Theoretically, the higher the number of missense mutations, the
higher expression of tumor neoantigens which can elicit the
greatest antitumor immune response and increase sensitivity to
ICI. A retrospective analysis from KEYNOTE-012 and -055 dem-
onstrated a stronger correlation between response to pembrolizu-
mab and high TMB and neoantigen load in the HPV– subgroup
than HPVþ subgroup [75]. As a matter of fact, in virally induced
tumors such as HPVþ tumors or Merkel-cell carcinoma, response
rates to ICI are higher than expected when adjusted for TMB and
compared with other tumors types, suggesting immune
responses may also be triggered by virus-specific antigens rather
than by tumor-neoantigens alone [39, 76–78]. In support of this,
a retrospective study analyzing a cohort of 126 patients with R/M
HNSCC treated with anti-PD-1/PDL-1 agents showed that
HPVþ patients had, as expected, lower TMB (8.2 versus 4.7 mut/
MB, P< 0.01) when compared with HPV– disease, while the
number of responses was similar (7 versus 10 responses,
P¼ 0.54) [73]. More importantly, among HPVþ patients, res-
ponders had increased CD8þ TILs regardless of TMB.
Overall, with the current available data, it is not possible to de-
termine whether HPVþOPSCC have higher (or lower) sensitivity
to ICI when compared with HPV– disease. HPV positivity alone
does not seem to be a reliable biomarker of response to ICI and
needs to be interpreted along with other companion clinical and
molecular biomarkers.
Is there a role for tumor immune infiltration and T-
cell-inflamed phenotypes?
Tumor immune infiltration implies initial recognition by the im-
mune system and might indicate an antitumor immune response
[79]. Multiple immune cells coexist within the TME, including
TILs (CD8þ T cells and Tregs), NK cells, macrophages, APC and
myeloid-derived suppressor cells. The composition of these
Review Annals of Oncology
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immune cells within TME, recently defined as immune contex-
ture, has prognostic implications but can also be predictive of re-
sponse to therapies [17, 61, 80]. For instance, CD8þ T-cell
infiltration at baseline has been correlated with increased re-
sponse to anti-PD-1/PD-L1 agents in melanoma [81, 82].
HNSCC tumors are highly immune-infiltrated but overall
characterized by an immunosuppressive TME [48, 83]. Many
retrospective studies have attempted to assess the prognostic and
predictive value of tumor immune cell infiltration (supplemen-
tary Table S1, available at Annals of Oncology online) [18, 62, 63,
84–89]. Despite the heterogeneity of these studies, increased infil-
tration by CD8þ T cells is the only immune cell type in HNSCC
consistently proven to be correlated with increased survival re-
gardless of tumor location, stage and treatment [61, 65]. A retro-
spective evaluation of 126 patients diagnosed with R/M HNSCC
treated with anti-PD-1/PD-L1 agents showed that increased
tumoral infiltration by CD8þ T cells and an increased ratio CD8þ
T cells/Tregs were positively correlated with treatment response,
indicating their potential role as predictive biomarkers [73].
In addition, the relative proportion of the various immune cell
subsets and their location within the TME may be of relevance in
predicting response to ICI. The immunoscore (IS) is a tool quan-
tifying the density of CD8þ T cells within the tumor center versus
the invasive margin. Increased number of CD8þ T cells in the
tumor center (high IS) is thought to indicate an effective antitu-
mor immune response and has been proven to be an independent
prognostic biomarker in early stage colorectal cancer, melanoma
and NSCLC [80, 90–92]. In HNSCC, a high IS is associated with
lower levels of Tregs, increased PD-L1 and MHC type I expres-
sions in tumor cells [62, 93], suggesting its potential to identify a
subset of tumors with increased sensitivity to anti-PD-1/PD-L1
therapy. However, the predictive role of IS in HNSCC has not
been explored yet.
The coexpression of other inhibitory immune-checkpoint
molecules such as TIM-3 (T-cell immunoglobulin and mucin
domain-containing protein 3), lymphocyte-activating gene 3
(LAG-3) and T-cell immunoreceptor with Ig and ITIM domains
(TIGIT) has also shown to impair immune T-cell-mediated
responses, conferring resistance to anti-PD-1/PD-L1 agents in
preclinical models and in patients across different tumor types
such as melanoma and NSCLC [15, 94–99]. In HNSCC, a recent
study showed intratumoral exhausted PD-1þ CD8þ T cells
expressing TIM-3 or LAG-3 were higher among nonresponders
to anti-PD-1 therapy [73]. In this regard, the predictive value of
response to ICIs offered by immunophenotyping of circulating
T-cell subsets versus TILs has demonstrated relevance in melan-
oma and NSCLC but it is still unknown in HNSCC [100, 101]. In
a substudy of CHECKMATE-141 evaluating treatment with
nivolumab beyond progression, responders had significantly
lower levels of circulating PD-1þ CD8þ T cells at baseline and
lower levels of PD-1þ Tregs at day 43, indicating circulating
exhausted T cells could be a negative predictive biomarker to
anti-PD-1/PD-L1 agents [102]. Although the available data are
still limited and should be interpreted with caution, determining
the coexpression of inhibitory checkpoint molecules in intratu-
moral and/or circulating T-cell subsets could be predictive of re-
sistance to anti-PD-1/PD-L1 agents and potentially indicate the
need for ICI combinations in selected cases of HNSCC.
Gene-expression profiling (GEP) signatures that identify
tumors with a T-cell-inflamed phenotype have shown promising
results in predicting response to anti-PD-1/PD-L1 agents [103,
104]. A 18-gene T-cell-inflamed signature including genes that
reflect an ongoing adaptive Th1 and cytotoxic CD8þ T-cell re-
sponse (including IFN-c signaling, cytolytic activity, antigen
presentation and T cell trafficking) has been tested in two
HNSCC cohorts from prospective clinical trials (KEYNOTE-012
and KEYNOTE-055) treated with single-agent pembrolizumab
showing a positive correlation with response and survival, re-
gardless of HPV status [74, 75]. This signature has been recently
validated in additional tumor cohorts from KEYNOTE-012 and -
028 studies, including melanoma and HNSCC. The study con-
firmed its predictive value as a biomarker of response to pembro-
lizumab and also revealed a positive correlation with PD-L1
expression by CPS [105].
Despite the prognostic implications and early data suggesting a
correlation between TILs and response to anti-PD-1/PD-L1 ther-
apy, prospective validation is needed. Moreover, identifying a T-
cell-inflamed phenotype and determining coexisting immune
cells and coexpression of other inhibitory immune checkpoint
molecules beyond PD-1/PD-L1 within the TME could be instru-
mental to differentiate tumors that will likely be responsive to
anti-PD-1/PD-L1 antibodies as single agents from those that may
benefit from combined ICI for efficacy.
Tumor mutational burden and HNSCC mutational
landscape
TMB has been recently evaluated as a potential biomarker of re-
sponse to immune checkpoint blockade in prospective clinical
trials and across many tumor types [77, 106–109]. An initial
retrospective analysis of 27 tumor types and subtypes among
patients who received PD-1/PD-L1 inhibitors demonstrated a
significant correlation between TMB and response rate to these
agents [77]. In this study, TMB was reported as a median number
of coding somatic mutations per megabase (N mut/MB).
Melanoma and squamous cell carcinoma of the skin (15–50 mut/
MB) followed by tobacco-related cancers including NSCLC, uro-
thelial cell carcinoma and HNSCC (5–10 mut/MB) comprised
malignancies with the highest TMB [77]. Retrospective subset
analyses of clinical trials evaluating pembrolizumab, atezolizu-
mab and nivolumab in metastatic melanoma, NSCLC, urothelial
carcinoma and HNSCC have demonstrated not only increased
ORR but also improved survival in patients with high TMB [75,
106–108, 110]. These results were consistent across the studies,
tumor type and anti-PD-1/PD-L1 agents. However, the cut-off
and measure used to define a high TMB differed between studies,
thus precluding direct comparisons. These results were further
supported by a retrospective analysis of 126 HNSCC patients
treated with anti-PD-1/PD-L1 agents. TMB was found to be sig-
nificantly higher among responders (21.3 versus 8.2 mut/MB,
P< 0.01) and was correlated with increased median OS
(20 months if TMB> 10 mut/MB versus 6 months if
TMB< 5 mut/MB, P¼ 0.01) in HPV– disease [73]. A combined
biomarker analysis of multiple studies evaluating the correlation
between TMB, T-cell-inflamed GEP, PD-L1 expression by CPS
and response to pembrolizumab in HNSCC showed no
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significant correlation between TMB and inflammatory bio-
markers (i.e. GEP or PD-L1). While this analysis did not stratify
by HPV status, it suggests TMB and inflammatory biomarkers
have distinct and independent predictive values, and may be used
orthogonally to identify responders to pembrolizumab [105].
In addition to TMB, the specific tumor mutational landscape
might be of biological relevance. Tumors characterized by muta-
tions affecting DNA damage response, such as those with micro-
satellite instability high (MSI-H) or mismatch repair deficiency
(dMMR), have the highest mutational load [77, 111]. These
tumors have been shown to be particularly sensitive to ICI in pro-
spective clinical trials, leading to the FDA approval of pembroli-
zumab for patients with dMMR or MSI-H tumors, regardless of
histology [112, 113]. The estimated incidence of MSI-H tumors
among HNSCC has been reported to be about 8% [114].
However, a recent study identified a subgroup of HNSCC res-
ponders to anti-PD-1/PD-L1 whose tumors were enriched with
somatic mutations derived from frameshift events in tumor sup-
pression genes such as NOTCH and SMARCA4 [73]. These cases
are similar to what has been described in tumors with dMMR,
with baseline increased mutational burden and greater sensitivity
to ICI. The authors suggested this finding might represent a novel
mutational signature in HNSCC with potential predictive value,
although further validation is warranted.
HNSCC genomic classification described by the TGCA might
be considered as well [39]. Four subtypes have been defined on
the basis of gene expression: atypical, mesenchymal, basal and
classical. The mesenchymal subtype, e.g. characterized by altera-
tions in genes related to innate immunity, downregulation of
MHC type I expression and deficient antigen-presentation ma-
chinery, would unlikely respond to anti-PD-1/PD-L1 agents.
Overall, while the predictive role of the specific molecular sub-
types is yet to be explored, TMB has shown promising results and
might become a useful predictive biomarker of immune-
checkpoint blockade efficacy in HNSCC. However, similar to
what occurred with the PD-L1 assay, the lack of uniformity in the
methods used to determine the mutational burden (e.g. meas-
ured in the tumor or in the blood) and the variability of the
thresholds used across studies are hampering the interpretation
and extrapolation of the results obtained. Thus, standardization
should be pursued when designing biomarker-validating studies
using TMB. Moreover, TMB has not shown to correlate with PD-
L1 expression or GEP signatures [73, 75, 105], again indicating
the interactions between the tumor, TME and the immune sys-
tem are complex and dynamic.
Introducing the microbiota as a potential
immune biomarker for HNSCC
The microbiota in head and neck cancer
The composition of the microbiota present in the oro-
gastrointestinal tract has been associated with immune dysregu-
lation and initiation and progression of many cancers [23, 115–
118]. The precise mechanisms of these associations are not
known, but compositional and functional changes in the micro-
biota can induce or exacerbate chronic inflammation, resulting
in cell damage and alteration of local and systemic immune
homeostasis, which may affect local and distant carcinogenesis,
ultimately dampening or enhancing antitumor immune
responses [116, 119]. HNSCC arise from an epithelium and
mucosae located in the oral cavity and the pharynx; both sites are
constantly exposed to environmental factors that can alter the
oral microbiota [120, 121]. Retrospective cohort studies have
shown different microbiota composition in the saliva of HNSCC
patients compared with healthy controls, while the presence of
specific bacteria has been associated with reduced risk of develop-
ing HNSCC [23, 122–124]. Moreover, differentially enriched
microbiota found in HPVþ and HPV– OPSCC and oral cavity
SCC indicates the existence of specific microbiota according to
tumor location and HPV status [24]. Nonetheless, some authors
have underlined the challenge of distinguishing whether the
changes observed in the oral microbiota from HNSCC patients
are influenced by the TME and/or by local and systemic cancer
therapies, since most of the studies to date have retrospectively
evaluated small, heterogeneous and noncontrolled cohorts of
patients comprising different tumor sites, variable disease stages,
and treatment with multiple modalities [23]. In this regard, a
study analyzing the oral microbiota present in the saliva of
HNSCC patients before and after treatment [including surgery,
chemoradiotherapy (CRT) and ICI] showed an association be-
tween specific oral bacteria composition (Fusobacterium and
Lactobacillus), down-regulation of immune-signaling pathways
and upregulation of oncogenic Wnt/Beta-catenin pathways
[125]. Altogether these findings suggest that the oral microbiota
might represent a promising prognostic and predictive biomark-
er in this disease (Figure 1).
Exploiting the microbiota as a biomarker of
response to immunotherapy
Accumulating evidence has implicated that intestinal micro-
biota can modulate host anticancer immune responses and alter
the efficacy of anticancer therapies, including immunotherapy
[19, 126–131]. Two preclinical studies using mouse models of
melanoma and lung cancer revealed a correlation between the
presence of specific commensal intestinal bacteria
(Bifidobacterium) and response to ICI [20, 132]. This was fur-
ther supported by two recent publications evaluating the gut
microbiome in patients with melanoma and epithelial-derived
tumors, showing improved anti-PD-1/PD-L1 efficacy among
patients harboring specific intestinal bacteria (the species of
Akkermansia muciniphila and members of the Ruminococcaceae
family) and higher microbial diversity [21, 22]. Remarkably,
these microbiota were also correlated with enhanced local and
systemic immune response, reduction in tumor growth and res-
toration of response to anti-PD-1/PD-L1 therapy in germ-free
mice transplanted with fecal microbiota from responding
patients. These latter findings indicate the potential modulation
of the microbiota as a viable therapeutic target to increase re-
sponse to ICI.
Whether the microbiota has a role in predicting response to
immunotherapy in HNSCC is yet to be determined. Only one
substudy from CHECKMATE-141 explored the role of the oral
microbiota measured in the saliva as a predictive biomarker in
patients with R/M HNSCC treated with nivolumab, showing no
Review Annals of Oncology
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significant correlation with treatment efficacy or survival
[9, 133]. However, the study had several limitations, including
the lack of uniformity in sample collection, the small number of
responses for correlation and importantly, the omission of intes-
tinal microbiota. The predictive role of the oral microbiota was
also investigated in melanoma patients treated with anti-PD-1/
PD-L1 therapy, again reporting no association with treatment
outcome, in contrast to the positive correlation observed with the
intestinal microbiota composition [22]. Differential bacterial
composition between these anatomical sites suggests oral and in-
testinal microbiota likely represent distinct entities with specific
disease associations.
Considering the immunomodulatory effects of the intestinal
microbiota and the growing evidence of the oral microbiota
impacting HNSCC tumorigenesis and progression, the study of
their role as a predictive biomarker of response to ICI in this dis-
ease is warranted. Hence, our group is currently conducting a re-
search study at the Princess Margaret Cancer Centre to
prospectively evaluate the oral and intestinal microbiota in a
homogeneous cohort of patients diagnosed with locoregionally
advanced OPSCC treated with definitive chemoradiotherapy.
The overarching goal of this project is to characterize and explore
the correlation with both oral and intestinal microbiota meas-
ured in the saliva and stool, respectively, by using 16S rRNA
sequencing, in order to obtain a deeper understanding of their
relationship with treatment response. The results of this ongoing
study will serve as a fundamental basis to evaluate oral and intes-
tinal microbiota signatures and their role as predictors of re-
sponse to ICI in patients treated within the CCTG HN.9 clinical
trial, a multicenter phase II noncomparative randomized study
evaluating ICI plus RT followed by maintenance ICI versus
standard chemoradiotherapy in intermediate-risk, HPVþ locore-
gionally advanced OPSCC (NCT034106615).
Discussion
Conclusion
Anti-PD-1 agents have become the standard of care for the
platinum-refractory R/M HNSCC. Results from clinical trials
evaluating their role in additional disease settings are pending,
but clearly such compounds are already an important therapeutic
backbone in this malignancy. As such, appropriate selection of
patients who will benefit from these therapies is crucial. To date,
there are no validated predictive biomarkers of response that are
applicable uniformly to all HNSCC patients, although many can-
didate biomarkers with promising results are undergoing investi-











































Figure 1. Interactions between the oral and intestinal microbiome, immune responses and the HNSCC TME. The composition of the oral micro-
biota alters the oral mucosae contributing to tumor development and progression in the context of other coexisting factors such as HPV infec-
tion. Intestinal and oral microbial composition and diversity regulate systemic and local immune responses modulating the TME along with other
immune biomarkers such as TMB or immune checkpoint protein expression, ultimately dampening or enhancing antitumor immune responses.
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annotated biomarker data would be invaluable to further the
knowledge in this field.
Most of the biomarkers in HNSCC have been explored retro-
spectively, often using baseline archival tumor samples at a single
time point which may not reflect the impact of spatial and tem-
poral intratumoral heterogeneity. Also, standalone evaluation of
potential biomarkers without considering interactions with other
factors is likely oversimplifying the complexity of immune re-
sponse. The microbiota is a dynamic and complex ecosystem that
interrelates the immune system and the TME, thus, potentially
representing an ideal biomarker that reflects the interactions be-
tween these biological entities in totality. Both oral and intestinal
microbiota may be important regulators of local and systemic
immune responses induced by environmental factors, shaping
the TME and ultimately modulating the efficacy of cancer thera-
pies. Considering the emerging immunomodulatory effects of
the microbiota, the study of its role as a predictive immune bio-
marker in HNSCC is of special interest and should be integrated
into prospective clinical trials.
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